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Satyanarayana Paturi,1,2 Sunil K. Karkala,3 Kevin M. Rice,1,2 and Eric R. Blough1–4
Abstract
Background: Age-related muscle atrophy is characterized by increased oxidative stress, diminished Akt enzy-
matic function, and reduced phosphorylation of the mammalian target of rapamycin (mTOR), which can be
attenuated by chronic acetaminophen ingestion. Here we hypothesize that age-related impairments in Akt/
mTOR function are associated with reduced protein translational signaling, and that these changes, if present,
can be attenuated by acetaminophen treatment.
Results: Compared to 6- and 27-month old animals, the expression of the mTOR-complex proteins raptor and
GbL and the phosphorylation of tuberin/TSC2 (Thr1462) were reduced in the soleus muscles of very aged rats
(33 months old). These changes in Akt/mTOR pathway signaling proteins were in turn associated with de-
creased phosphorylation of S6 kinase p85S6K (Thr412) and eukaryotic translation initiation factor-4E (eIF4E)
binding protein-1 (4EBP1, Thr37/46), reduced phosphorylation of S6 ribosomal protein (Ser235/236), and in-
creased inhibition of eIF4E by binding to 4EBP1. Age-associated alterations in the Akt/mTOR pathway signaling
and in the phosphorylation of the stress-responsive eIF2a protein were attenuated by chronic acetaminophen
treatment (30mg/kg body weight per day). Ex vivo incubation of adult muscles with hydrogen peroxide
mimicked the age-related decreases seen in eIF4E and 4EBP1 phosphorylation, whereas the inclusion of acet-
aminophen in the muscle bath attenuated this effect.
Conclusion: Aging is associated with impairments in the regulation of proteins thought to be important in
controlling mRNA translation, and acetaminophen may be useful for the treatment of age-related muscle at-
rophy by reducing oxidative stress.
Introduction
The age-associated loss of skeletal muscle mass andmuscle strength, or sarcopenia, has a profound effect on
quality of life and is of significant socioeconomic interest.1–3
The accumulation or loss of muscle protein is determined by
the balance between muscle protein synthesis and degrada-
tion. The factors regulating the initiation and progression of
sarcopenia are not fully understood; however, recent data
have demonstrated that the rate of muscle protein synthesis
is decreased in advanced age of human and different animal
models4–6 and that this effect may be mediated, at least in
part by the reactive oxygen species (ROS) levels.7–10 How
increased age or ROS levels may affect the regulation of
protein synthesis is not well understood.
The mammalian target of rapamycin (mTOR) pathway is a
critical regulator of protein synthesis,6,11,12 whose activity is
regulated by phosphorylation at Ser2448 (via protein kinase
B/Akt13,14) and by binding to its regulatory partners, the
regulatory associated protein of mTOR (raptor) and GbL15–17
(both positive regulators), or Tuberin/TSC2,13,14 (negative
regulator). Regulation of protein translation by mTOR is ef-
fected through the phosphorylation of S6 kinase, which
functions to phosphorylate the S6 ribosomal protein18,19 and
eukaryotic translation initiation factor-4E (eIF4E) binding
protein-1 (4EBP1), with the latter event leading to the release
of eIF4E from 4EBP1, a step necessary for initiation of mRNA
translation.20–24 Like eIF4E, the eIF2 also plays a role in
regulating translational initiation because it mediates the bind-
ing of initiator methionyl-tRNA and guanosine triphosphate
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(GTP) to the ribosome 40S subunit.25,26 The ability of eIF2 to
regulate initiation is inhibited, at least in part, under conditions
of elevated stress, which can lead to the phosphorylation of the
eIF2 a subunit (eIF2a) and the formation of a stable eIF2–GDP–
eIF2B complex.25,26 Whether aging or increased oxidative stress
affects the amount or phosphorylation of molecules thought to
participate in the regulation of protein synthesis rates has to
our knowledge not been investigated.
Previous studies from our laboratory have demonstrated
that age-related muscle atrophy is characterized by increased
tissue ROS levels, impaired Akt enzymatic function, de-
creased mTOR phosphorylation/activation, diminished
myocyte size, and decreased expression of the contractile
proteins myosin and actin.7,10 Other work from our labora-
tory has demonstrated that chronic acetaminophen ingestion
can be used to attenuate these age-related changes in Akt/
mTOR signaling and muscle structure.10 Using the same
animals and tissues that we examined previously,10 here we
hypothesize that impairments in Akt/mTOR signaling will
be accompanied by a dysregulation of downstream protein
translational signaling and that chronic acetaminophen in-
gestion can be used to ameliorate these age-associated
changes. Although incapable of proving cause and effect, the
data of the present study suggest that acetaminophen may be




Primary antibodies against tuberin/TSC2 (#3612), phos-
pho-tuberin/TSC2 (Thr1462) (#3617), GbL (#3274), raptor
(#2280), p70S6 kinase (#9202), phospho-p70S6 kinase
(Thr389) (#9205), S6 ribosomal protein (#2217), phospho-S6
ribosomal protein (Ser235/236) (pS6, #4858), eIF4E (#2067),
phospho-eIF4E (Ser209) (#9741), 4EBP1 (#9452), phospho-
4EBP1 (Thr37/46) (#9459), eIF2a (#9722), phosphor-eIF2a
(Ser51) (#3597), glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, #2118), secondary antibodies conjugated with
horseradish peroxidase (HRP) (anti-rabbit [#7074] or anti-
mouse [#7076]) were purchased from Cell Signaling Tech-
nology (Beverly, MA). Protein A/G PLUS Agarose (sc-2003)
were from Santa Cruz Biotechnology (Santa Cruz, CA). The
Laemmli 4 sample buffer was from Sigma-Aldrich (St.
Louis, MO). Pierce Tissue Protein Extraction Reagent (T-
PER), Pierce 660nm protein assay reagent (#22660), GE
Healthcare Amersham ECL Western Blotting Detection
Reagents (RPN 2106), and Advance Western Blotting De-
tection Kit (RPN2135) were from Thermo Fisher Scientific
Inc. (Rockford, IL). The PAGEr Gold Precast gels (10%) were
from purchased from Lonza (Rockland, ME).
Animals
Animal care and procedures were conducted in accor-
dance with the Animal Use Review Board of Marshall Uni-
versity using the criteria outlined by the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) as proclaimed in the Animal Welfare Act (PL89-
544, PL91-979, and PL94-279). The animals and tissues used
in this study have been previously examined.10 Six- and 27-
month-old male Fischer 344/NNiaHSDXBrown Norway/
BiNia F1 (F344BN) rats were procured from the National
Institute on Aging (Bethesda, MD) and housed in an
AAALAC approved vivarium with a 12:12 h light/dark cycle
and at the temperature of 22 28C. Two animals were
kept in each cage with ad libitum access to water and
food (LabDiet 5001, PMI Nutrition International, LLC,
Brentwood, MO).
Acetaminophen treatment and tissue collection
The 27-month-old F344BN rats were daily given acet-
aminophen (30mg/kg body weight per day) continuously for
6 months in their drinking water (denoted as 33T). Age-
matched rats were maintained as controls (33C). Soleus
muscles were removed from anesthetized animals under an-
esthesia using a ketamine–xylazine (4:1) cocktail (50mg/kg,
intraperitoneally), frozen in liquid nitrogen, and stored at
808C.
Ex vivo muscle incubation
Two strips of muscle were isolated from each soleus
muscle from 6-month-old rats and mounted to plastic plates
to keep them at their in situ resting length. The ex vivomuscle
incubation were performed at 258C in Krebs Henseleit buffer
(KHB, pH 7.4), that had been equilibrated with 95% O2 and
5% CO2 as described previously.
10 After preincubation in
KHB for 15min, muscles were incubated in KHB for another
40min (control), or in KHB containing hydrogen peroxide
(H2O2) (200mM) and/or acetaminophen (1.65mM) for 20min
each. The acetaminophen concentration (1.65mM) was
equivalent to that in drinking water provided for rats.
Muscle samples were then washed with KHB, immediately
frozen in liquid nitrogen, and stored at 808C.
Tissue protein extraction
Soleus muscles were homogenized in a Pierce Tissue
Protein Extraction Reagent (T-PER) (10mL/g tissue) con-
tained protease inhibitors (P8340; 1:100) and phosphatase
inhibitors (P5726; 1:100), and then sonicated for 0.5min three
times at 48C. The homogenate was collected by centrifuging
at 12,000 g for 5min at 48C. Protein concentration of ho-
mogenates was determined using a Pierce 660nm protein
assay reagent (#22660). The homogenate were boiled in
Laemmli 4 sample buffer for 5min for further immuno-
blotting analysis.
Determination of eIF4E/4EBP1 association
The binding of 4EBP1 to eIF4E were determined by co-
immunoprecipitation. Briefly, 200 mg of homogenate (180mL)
was incubated with anti-eIF4E antibody (1:50 dilution) and
20 mL of protein A/G PLUS Agarose (sc-2003) overnight
at 48C. Agarose beads were collected by centrifuging at
8,000g for 30 sec at 48C, and washed with 500 mL of T-PER
buffer containing protease (P8340; 1:100) and phosphatase
inhibitors (P5726; 1:100) three times. Forty microliters of
Laemmli 2 sample buffer was added to the pellet, and the
samples were boiled for 5min. Twenty microliters of each
supernatant was used for immunoblotting analysis to detect
the abundance of 4EBP1.
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Immunoblotting analysis
Immunoblotting analysis were performed to detect target
proteins as described previously.7,10 Briefly, protein samples
was separated on a 10% PAGEr Gold Precast gel and then
transferred to nitrocellulose membranes. After incubation with
primary antibody overnight at 48C and secondary antibody for
1 h at room temperature, target proteins were visualized fol-
lowing reaction with GE Healthcare Amersham ECL Wes-
tern Blotting Detection Reagents (RPN 2106) or Advance
Western Blotting Detection Kit (RPN2135). Target protein
levels were quantified using AlphaEaseFC image analysis
software (Alpha Innotech, San Leandro, CA) and normalized
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Data analysis
Results are presented as mean standard error (SE). The
effects of age and acetaminophen treatment were analyzed
using the general linear model (GLM) procedure (SAS 9.1 for
Windows, SAS Institute Inc., Cary, NC). Means were calcu-
lated by the least-squares means (LSMEANS) procedure,
and multiple comparisons were performed using the Tukey–
Kramer test to determine differences between groups. Values
of p< 0.05 were considered to be statistically significant.
Results
Acetaminophen restores tuberin/TSC2
phosphorylation in aged skeletal muscle
The phosphorylation of the mTOR negative regulator tu-
berin/TSC2 at Thr1462 was decreased in the soleus of 33-
month-old aged control rats (55.7% and 68.4% when
compared to that in 6- and 27-month-old rats; p< 0.05;
Fig. 1). Chronic acetaminophen treatment restored the
tuberin/TSC2 phosphorylation level to that observed in the
adult (6-month) rat ( p> 0.05; Fig. 1).
Acetaminophen attenuates aging-associated
reductions in mTOR-complex regulators
Compared to that found in 27-month-old animals, the
expression of the mTOR-complex proteins raptor and GbL
were decreased in 33-month aged control rats (26.8%
and 15.0%, respectively; p< 0.05; Fig. 2A,B). Chronic
acetaminophen treatment increased both raptor and GbL
expression compared to that in 33-month control rats (13.9%
and 11.4%, respectively; p< 0.05; Fig. 2A,B).
FIG. 1. Acetaminophen restores tuberin/TSC2 phosphor-
ylation in aged skeletal muscle. Tuberin/TSC2 total protein
and the phosphorylation of tuberin/TSC2 at Thr1462 in so-
leus muscle from 6-, 27-, 33-month-old control (33C) and
acetaminophen-treated (33T) F344BN rats were determined
by immunoblotting. Data are mean standard error. (abc)
Groups without the same letter are significantly different
( p< 0.05).
FIG. 2. Acetaminophen attenuates aging-associated reduc-
tions in the amount of raptor and GbL. Raptor (A) and GbL
(B) protein levels in 6-, 27-, 33-month-old controls (33C) and
acetaminophen-treated (33T) rats as determined by immu-
noblotting. Data are mean standard error. (abc) Groups
without the same letter are significantly different ( p< 0.05).
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Age-associated reductions in the phosphorylation
of S6 kinase and S6 ribosomal protein in muscle
are attenuated by acetaminophen
The abundance of phosphorylated S6 kinase p85S6K
(Thr412) in the aged soleus was lower than that in the 6- and
27-month animals (39.6% and 46.8%, respectively;
p< 0.05; Fig. 3A), while chronic acetaminophen treatment
restored the amount of phosphorylated p85S6K to a level
equivalent to that seen in 6- and 27-month old animals
( p> 0.05; Fig. 3A). Phosphorylation of S6 kinase p70S6K
(Thr389) was increased with aging ( p< 0.05; Fig. 3A), and
chronic acetaminophen treatment increased p70S6K phos-
phorylation compared to that in 33-month control rats
(22.2%; p< 0.05; Fig. 3A). Compared to that observed in 27-
month animals, the phosphorylation of S6 ribosomal protein
at Ser235/236 was decreased in the soleus of 33-month aged
control rats (23.3%; p< 0.05; Fig. 3B), whereas chronic
acetaminophen treatment restored the phosphorylated level
of S6 ribosomal protein to that seen in 27-month rats
(P> 0.05; Fig. 3B).
Acetaminophen intervention reduces the inhibitory
effect of 4EBP1 on eIF4E in aged muscle
Compared to that seen in the 6- and 27-month-old rats, the
phosphorylation of translational initiation factor eIF4E at
Ser209 was decreased in the soleus of 33-month aged control
rats (51.7% and 39.3%, respectively; p< 0.05; Fig. 4A).
Chronic acetaminophen treatment restored eIF4E phos-
phorylation to levels observed in 6- and 27-month-old rats
( p> 0.05; Fig. 4A). The abundance of phosphorylated 4EBP1
(Thr37/46) in the aged soleus was lower than that found in
the 6- and 27-month-old animals (17.2% and 12.3%, re-
spectively; p< 0.05; Fig. 4B), while it was increased after 6
months of chronic acetaminophen treatment (þ36.4%,
p< 0.05; Fig. 4B). Co-immunoprecipitation experiments
demonstrated that the abundance of 4EBP1 bound to eIF4E
was increased in the soleus of 33-month-old aged control rats
when compared to that in 27-month-old rats (þ32.9%,
p< 0.05; Fig. 4C) and that chronic acetaminophen treatment
decreased this binding by 21.7% ( p< 0.05; Fig. 4C).
To investigate whether oxidative stress affects the activa-
tion of eIF4E, muscle strips from control adult animals were
incubated with H2O2 and/or acetaminophen for 20min. The
inclusion of H2O2 to the muscle bath decreased phosphory-
lation of eIF4E and 4EBP1 whereas this effect was reversed
by the addition of acetaminophen to the muscle bath
(Fig. 4D). Incubation with acetaminophen alone had no effect.
Acetaminophen reduces phosphorylation
of eIF2a in aged skeletal muscle
Compared to 6-month-old animals, the phosphorylation
of eIF2a at Ser51 was increased in the soleus of 33-month-old
aged control rats (þ19.5%; p< 0.05; Fig. 6). Chronic acet-
aminophen treatment restored the eIF2a phosphorylation to
a level similar to that observed in the 6- and 27-month-old
rats.
Discussion
Age-related decreases in muscle protein synthesis are
thought to play a significant role in the loss of muscle mass
that occurs during aging.4,5 The main finding of this study is
that aging in the F344BN rat model is characterized by al-
terations in the phosphorylation status of ribosomal protein
S6, eIF2a, eIF4E, and 4EBP1. This latter modification is ac-
companied by increased binding of 4EBP1 to eIF4E, which
would be predicted to impair the initiation step of protein
synthesis. In addition, it appears that the inhibition of eIF4E
by 4EBP1 may be mediated, at least partially, by increased
FIG. 3. Reductions in the amount of phosphorylation of S6
kinase and S6 ribosomal protein with aging are attenuated
by chronic acetaminophen ingestion. (A) S6 kinase p85S6K
(Thr412) and p70S6K (Thr389) protein levels in 6-, 27-, 33-
month-old control (33C) and acetaminophen-treated (33T)
rats. (B) The phosphorylation (Ser235/236) and total protein
of S6 ribosomal protein as determined by immunoblotting.
Data are mean standard error. ( abcd) Groups without the
same letter are significantly different ( p< 0.05).
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oxidative stress, as ex vivo muscle incubation with H2O2
acutely reduced eIF4E and 4EBP1 phosphorylation. Im-
portantly, these age-associated alterations were attenuated
by chronic acetaminophen intervention using a dosage
(30mg/kg body weight per day) that has previously been
found to be safe and well tolerated.7
mTOR plays an important role in the stimulation of
myocyte growth and prevention of muscle atrophy.6,11,12 It
is thought that the mTOR activity is stimulated by phos-
phorylation of Ser2448 by Akt13,14 and by the binding
of mTOR to raptor and GbL.15–17 Conversely, mTOR activ-
ity has been shown to be inhibited following binding with
Tuberin/TSC2 in a process that is negatively regulated
through the phosphorylation of Tuberin/TSC at Thr1462 by
Akt/PKB.13,14
Previous data from our laboratory have demonstrated that
age-associated impairments in Akt/mTOR signaling are
characterized by a mismatch between the degree of Akt
phosphorylation and the activation of its downstream sub-
strates mTOR and GSK-3b.10 Similar instances of Akt ‘‘un-
coupling’’ have been reported in human studies following
the infusion of amino acids and insulin, and with exer-
cise.27,28 Further studies have indicated that although higher
Akt phosphorylation (Ser473 and Thr308) is observed, Akt
kinase enzymatic activity is impaired in aged atrophic skel-
etal muscle and that this impairment contributes to the re-
duced phosphorylation of mTOR because reversal of Akt
dysfunction by acetaminophen is associated with increased
mTOR phosphorylation.10 Supporting our previous find-
ings of reduced Akt activity,10 we observed a reduction of
tuberin/TSC2 (Thr1462) phosphorylation with aging (Fig. 1).
This effect was reversed by chronic acetaminophen ingestion,
a finding that is consistent with the notion that alterations in
tuberin/TSC2 phosphorylation may be involved in reducing
mTOR activation in aged skeletal muscle.
To further investigate how mTOR function may be altered
in aged skeletal muscle, we next determined the expression
of the mTOR-binding proteins, raptor and GbL, and the
FIG. 4. Acetaminophen reduces the inhibitory effect of eukaryotic initiation factor 4E binding protein (4EBP1) on eukaryotic
initiation factor 4E (eIF4E) in aged muscle. eIF4E total protein and phosphorylation of eIF4E at Ser209 in 6-, 27-, 33-month-old
controls (33C) and acetaminophen-treated (33T) rats (A). Phosphorylation (Thr37/46) and total protein of eIF4E binding
protein-1 (4EBP1 or PHAS-1) (B). Binding of 4EBP1 to eIF4E as determined by co-immunoprecipitation and immunoblotting
(C). Soleus muscle strips from 6-month control animals were ex vivo incubated with hydrogen peroxide (H2O2) and/or
acetaminophen as described in Materials and Methods. Phosphorylation of eIF4E and 4EBP1 after ex vivo incubation were
detected by immunoblotting (D). Muscle incubated with Krebs Henseleit buffer () was used as control of H2O2 and
acetaminophen response. Data are mean standard error. (abc) Groups without the same letter are significantly different
( p< 0.05). H2O2, hydrogen peroxide; APAP, Acetaminophen.
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phosphorylation of two critical mTOR-substrates, S6 kinase
and 4EBP1. It has been postulated that the interaction of
raptor with mTOR is required for the phosphorylation of S6
kinase and 4EBP1 by mTOR15,16 and that this event is reliant
on GbL, which has been shown to stabilize the raptor–mTOR
interaction.17 In agreement with our findings of decreased
mTOR expression in aged skeletal muscle,10 here we dem-
onstrate that the expression of both raptor and GbL is di-
minished with aging (Fig. 2A,B). This finding could be
predicted to diminish mTOR function, a notion that is sup-
ported by our observation that aging is associated with
diminished phosphorylation of the two critical mTOR-
substrates, S6 kinase and 4EBP1 (Figs. 3A and 4B). Similar to
our findings with tuberin/TSC2, these age-related changes
in S6 kinase and 4EBP1 phosphorylation were reversed with
chronic acetaminophen ingestion (Figs. 3A and 4B). Taken
together, these data suggest that mTOR function is impaired
in aged skeletal muscle and that chronic acetaminophen in-
gestion may be useful for the prevention of age-associated
mTOR dysfunction in skeletal muscle.
The phosphorylation of the S6 ribosomal protein by
S6 kinase is critical for the translation of ribosomal proteins
and the elongation factors required to increase the syn-
thetic potential of the cell.18,19 In the present study, we
found that the phosphorylation of S6 ribosomal protein at
Ser235/236 was lower in very aged muscle (33-month)
compared to that observed in the muscles obtained from
27-month-old rats, and that this decrease was associated
with reduced phosphorylation of S6 kinase, p85S6K
(Fig. 3A,B). Consistent with the data for S6 kinase and
4EBP1, we also demonstrate that the phosphorylation of
p85S6K and S6 ribosomal protein can be preserved with
chronic acetaminophen ingestion, suggesting once again
that acetaminophen may be helpful for the treatment of
age-associated muscle atrophy.
The eukaryotic translation initiation factor eIF4E is
thought to bind with the mRNA 50-cap structure and medi-
ate the initiation of translation, a rate-limiting step for mRNA
translation.23,24 The binding of eIF4E to the mRNA 50-cap
structure is inhibited if eIF4E is sequestered by 4EBP1. This
process is regulated by phosphorylation state of 4EBP1, be-
cause the phosphorylation of 4EBP1 by mTOR prevents its
binding to eIF4E.20–22 In agreement with our previous find-
ing of the ability of mTOR to phosphorylate S6 kinase, we
found that the phosphorylation of 4EBP1 is reduced in aged
skeletal muscle (Fig. 4B). To further examine the potential
functional ramifications of these data we next performed co-
immunoprecipitation experiments, using an antibody to pull
down eIF4E and then probing the immunocomplex for the
presence of 4EBP1. As expected from our 4EBP1 phosphor-
ylation data, we found that the binding of 4EBP1 to eIF4E is
increased in aged skeletal muscle (Fig. 4C). These results,
along with our finding of a decreased phosphorylation of
eIF4E with aging, may suggest that aging in the skeletal
muscles of the F344BN rat may be associated with an im-
pairment of the processes regulating the initiation of trans-
lation and that alterations in Akt/mTOR signaling may
contribute to this condition. Interestingly, we also observed
that this age-associated increase in 4EBP1 and eIF4E inter-
action was diminished following chronic acetaminophen
ingestion, a finding that is supportive of the possibility that
acetaminophen ingestion may also increase mTOR activity
(Fig. 5).
To better understand if changes in oxidative stress may
participate in regulating the association between eIF4E and
4EBP1, we performed a series of ex vivo incubation experi-
ments where we added H2O2 to the muscle bath. We found
that the inclusion of H2O2 to the bath decreased the phos-
phorylation of eIF4E and 4EBP1 and that these decreases in
phosphorylation could be attenuated by the presence of
acetaminophen (Fig. 4D). These data are in agreement with
the possibility that age-associated increase in oxidative stress
could play a role in affecting the ability of the aged muscle to
initiate protein synthesis by its ability to increase the phos-
phorylation of eIF4E and 4EBP1. This postulate is consistent
with previous data from our laboratory that have demon-
strated that chronic acetaminophen ingestion in the aged rat
is associated with diminished age-related increases in muscle
ROS, oxidatively modified proteins, and decreased hyper-
activation of stress-responsive kinase p38–mitogen-activated
protein kinase (MAPK).7
In an effort to further examine the potential adverse effects
of oxidative stress on processes associated with the initiation
step of protein synthesis, we measured the phosphorylation
of eukaryotic initiation factor eIF2a. eIF2 mediates the
binding of initiator methionyl-tRNA and GTP to the ribo-
some 40S subunit and participates in forming the 43S pre-
initiation complex.26 It is thought that this process is
inhibited by eIF2a phosphorylation,25,26 with the latter also
occurring under conditions of increased oxidative stress.29,30
Here we observed that phosphorylation of eIF2a at Ser51
is increased with aging and that chronic acetaminophen
treatment was associated with a return of phosphorylated
eIF2a to a level observed in the 6- and 27-month-old ani-
mals (Fig. 5). These findings are consistent with recent data
FIG. 5. Acetaminophen reduces the phosphorylation of
eukaryotic initiation factor 2a-subunit (eIF2a) in aged skele-
tal muscle. eIF2a total protein and phosphorylation of
eIF2a at Ser51 in 6-, 27-, 33-month-old control (33C) and
acetaminophen-treated (33T) rats. Data are mean standard
error. (ab) Groups without the same letter are significantly
different ( p< 0.05).
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demonstrating that high glucose (hyperglycemia) increases
the phosphorylation of eIF2a.31 In addition, this finding is in
agreement with previous work from our laboratory showing
that aging is associated with increased blood glucose and that
chronic acetaminophen ingestion can be used to reverse age-
related hyperglycemia.7 Taken together, these data support
the possibility that age-associated hyperglycemia and/or in-
creases in oxidative stress may decrease translational initia-
tion by altering the phosphorylation status of eIF2a.
Although the effects of aging on tissue ROS levels have
been investigated extensively, much less is known about
how aging may affect the expression of molecules thought to
be important in counteracting ROS. It is thought that the
amount and activity of antioxidant enzymes are increased
during the initial phases of aging before undergoing a
gradual, but steady decline as the aging process pro-
gresses.32,33 Recent work using Cu2þ/Zn2þ superoxide dis-
mutase (SOD) (SOD1) transgenic mice have suggested a link
between the expression of SOD1 and eIF2a phosphoryla-
tion.34 Previous studies have demonstrated that acetamino-
phen exhibits potent antioxidant activity,35–39 and that
acetaminophen can decrease age-associated increases in
muscle ROS and iron-induced cardiac damage.7,40 Although
not investigated here, given these data, it is possible that
acetaminophen could have functioned to improve transla-
tional signaling via either its antioxidant activity or perhaps
by altering the expression of molecules involved in scav-
enging cellular ROS. Future experiments designed to directly
test this possibility will no doubt be useful in furthering our
understanding of how oxidative stress may be associated
with changes in protein synthesis and the regulation of
muscle mass during aging.
In summary, we found that aging in the F344BN rat
skeletal muscle is associated with alterations in the amount
or phosphorylation of tuberin/TSC2, raptor, GbL, p85S6K,
S6 ribosomal protein, eIF4E, 4EBP1, and eIF2a. In addition,
we also noted evidence of increased interaction between
eIF4E and 4EBP1. These changes, considered together, would
be predicted to decrease the ability of the aged muscle to
initiate and undergo protein synthesis. This finding is sup-
portive of previous work demonstrating that age-associated
increases in Akt S-nitrosylation lead to impaired Akt func-
tion and mTOR activation in the muscles of the aged
F344BN.10 In this aforementioned study, we found that
chronic acetaminophen treatment was associated with a re-
versal of Akt function and mTOR phosphorylation.10 We
find a similar effect here given that acetaminophen ingestion
was associated with a reversal in either the expression or
phosphorylation of tuberin/TSC2, raptor, GbL, p85S6K, S6
ribosomal protein, eIF4E, 4EBP1, and eIF2a to levels similar
to that found in their younger counterparts. In addition, we
also observed that acetaminophen treatment diminished the
possible inhibitory effects of tuberin/TSC2 and 4EBP1 on
protein synthesis by increasing phosphorylation of these
molecules. These improvements are in agreement with our
previous findings that chronic acetaminophen ingestion is
capable of attenuating age-associated changes in muscle
cross-sectional area and the incidence of myocyte apopto-
sis.10 The data of the present study, considered together with
our previous work demonstrating that acetaminophen di-
minishes muscle ROS levels and improves Akt function, lead
to further credence of the possibility that chronic acetamin-
ophen ingestion may be useful for the treatment of age-
related muscle atrophy (Fig. 6).
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